Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Apr 20, 2023 1:45pm
143 Views
Post# 35405699

RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)
Interesting find!

I'm confused about the protocol.

"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36."

So they complete treatment after induction of 6 weeks but sometimes need another 6 weeks of treatment? And then they keep getting study drugs at months 6,9,12,18. If there is residual disease but at a level that is very small, the repeated treatments for the second round of 6 weeks and then the month 6,9, 12,18 seem to me to be them just constantly chasing down the disease before it reaches a large enough size to be detectable. They call it maintenance but I feel that constantly giving the drug is a treatment type intervention which make is hard to say that the CR is durable....if you are still getting treated.

Does that make sense?

With Ruvidar the same thing could be said of the 180 day treatment but the patients who have no disease at 270,360, 450 and beyond are truly showing no return of disease. The original 1b patients are the best examples as they are years out now.
<< Previous
Bullboard Posts
Next >>